| Summary: | Brittany T Jackson,1 David B Cluck,2 Andrés F Henao-Martínez,3 Daniel B Chastain4 1Department of Pharmacy, Mount Sinai Morningside, New York, NY, 10025, USA; 2Department of Pharmacy Practice, Bill Gatton College of Pharmacy East Tennessee State University, Johnson City, TN, 37614, USA; 3Division of Infectious Diseases, University of Colorado, Anschutz Medical Campus, Aurora, CO, 80045, USA; 4Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, GA, 31701, USACorrespondence: Brittany T Jackson, Department of Pharmacy, Mount Sinai Morningside, New York, NY, 10025, USA, Email brittany.jackson@mountsinai.orgAbstract: Kimyrsa is a new formulation (NF) of the original formulation of oritavancin ([OF] Orbactiv). Comparatively, the obvious benefit with this product is the shortened infusion time and flexibility with solution compatibility, but otherwise maintains a similar pharmacokinetic and microbiologic profile. At present, the NF lacks significant real-world experience relative to other available lipoglycopeptides and thus its place in therapy remains difficult to predict but would not be expected to be significantly different than its OF.Keywords: Kimyrsa, Orbactiv, oritavancin, glycopeptides, ABSSSI, soft tissue infections, pharmacokinetics
|
|---|